FibroGen, Inc. (FGEN) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 1073.56
P/B Ratio
↓
N/A
—
5yr avg: 165.41
30Y Low142.1·High191.7
ROE
↓
N/A
—
5yr avg: -127.8%
30Y Low-258%·High-13%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FGEN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
FibroGen, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $585M | $1.3B | $2.2B | $37.5B | $32.6B | $83.3B | $92.9B | $97.3B | $86.5B | $33.6B | $46.0B |
| Enterprise Value | $625M | $1.4B | $2.2B | $37.4B | $32.5B | $82.7B | $92.8B | $97.3B | $85.9B | $33.5B | $45.9B |
| P/E Ratio → | -15.63 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 19.75 | 44.72 | 46.07 | 266.32 | 138.34 | 472.54 | 362.04 | 456.71 | 688.24 | 186.93 | 254.17 |
| P/B Ratio | — | — | — | — | 142.08 | 188.74 | 173.50 | 184.04 | 148.49 | 191.70 | 233.52 |
| P/FCF | — | — | — | — | — | 1073.56 | — | — | — | 5732.25 | — |
| P/OCF | — | — | — | — | — | 1021.02 | — | — | — | 4722.57 | — |
P/E links to full P/E history page with 30-year chart
FGEN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 46.06 | 47.28 | 265.85 | 138.04 | 468.91 | 361.75 | 456.75 | 683.66 | 186.50 | 253.86 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 1065.33 | — | — | — | 5719.20 | — |
FGEN Profitability
Margins and return-on-capital ratios measuring operating efficiency
FibroGen, Inc. earns an operating margin of -507.8%. Operating margins have compressed from -213.9% to -507.8% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.5% | 47.5% | 91.5% | 85.6% | -90.9% | 95.0% | 99.6% | -10.7% | -56.4% | -4.2% | -18.4% |
| Operating Margin | -507.8% | -507.8% | -689.5% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -97.6% | -29.9% | -42.9% |
| Net Profit Margin | -160.6% | -160.6% | -607.3% | -208.7% | -123.3% | -107.4% | -30.0% | -40.6% | -100.4% | -34.3% | -47.4% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -258.0% | -86.5% | -38.8% | -14.5% | -15.6% | -33.3% | -33.2% | -39.2% |
| ROA | -14.9% | -14.9% | -55.0% | -42.4% | -36.2% | -22.5% | -8.9% | -9.7% | -18.4% | -13.1% | -18.0% |
| ROIC | — | — | — | -500.0% | -137.3% | -109.1% | -13.4% | -24.0% | -174.8% | -33.6% | -37.2% |
| ROCE | -104.8% | -104.8% | -119.0% | -68.0% | -47.6% | -27.1% | -11.6% | -10.7% | -20.0% | -13.3% | -18.8% |
FGEN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $40M ($90M total debt minus $50M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.44 | 0.09 | 0.10 | 0.18 | 0.17 | 0.56 | 0.49 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.31 | -1.45 | -0.14 | 0.01 | -0.99 | -0.44 | -0.29 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -8.23 | — | — | — | -13.05 | — |
| Interest Coverage | -18.24 | -18.24 | -39.87 | -209.05 | -268.40 | -79.88 | -31.05 | -7.89 | -12.63 | -5.00 | -7.04 |
FGEN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.47x means FibroGen, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.80x to 1.47x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 9.69 | 4.09 | 2.99 |
| Quick Ratio | 1.45 | 1.45 | 1.33 | 1.65 | 1.96 | 4.53 | 6.77 | 7.75 | 9.69 | 4.09 | 2.99 |
| Cash Ratio | 0.38 | 0.38 | 1.08 | 1.54 | 1.80 | 4.21 | 5.19 | 6.98 | 9.52 | 3.89 | 2.70 |
| Asset Turnover | — | 0.14 | 0.11 | 0.23 | 0.30 | 0.21 | 0.30 | 0.24 | 0.14 | 0.38 | 0.38 |
| Inventory Turnover | 4.93 | 4.93 | 0.10 | 0.50 | 14.48 | 0.54 | 0.17 | — | — | — | — |
| Days Sales Outstanding | — | 5.93 | 320.16 | 42.27 | 39.40 | 86.70 | 218.60 | 109.15 | 24.55 | 21.24 | 31.09 |
FGEN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
FibroGen, Inc. returns 0.3% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.2% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 0.1% | — | — | — | 0.0% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.3% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $100M | $97M | $94M | $92M | $90M | $87M | $84M | $73M | $63M | $60M |
Peer Comparison
Compare FGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FGENYou | $585M | -15.6 | — | — | 47.5% | -507.8% | — | — | — |
 AKBA | $284M | -51.0 | 12.8 | 4.2 | 83.3% | 9.9% | -16.4% | 23.2% | 8.7 |
 PTCT | $7B | 10.8 | 7.3 | 10.0 | 95.9% | 49.5% | — | — | 0.5 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 INSM | $22B | -16.1 | — | — | 79.4% | -194.0% | -249.3% | -86.5% | — |
 ARWR | $11B | -6541.8 | 93.1 | 71.7 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 GILD | $155B | 18.5 | 11.9 | 16.4 | 78.8% | 39.7% | 40.7% | 23.2% | 1.7 |
 BMRN | $11B | 31.9 | 16.9 | 15.2 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 INVA | $2B | 7.2 | 7.2 | 8.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 HALO | $8B | 27.8 | 11.6 | 13.1 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
| Healthcare Median | — | 22.5 | 14.3 | 19.1 | 63.6% | -4.8% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
FGEN — Frequently Asked Questions
Quick answers to the most common questions about buying FGEN stock.
What is FibroGen, Inc.'s P/E ratio?
FibroGen, Inc.'s current P/E ratio is -15.6x. This places it at the 50th percentile of its historical range.
Is FGEN stock overvalued?
Based on historical data, FibroGen, Inc. is trading at a P/E of -15.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is FibroGen, Inc.'s dividend yield?
FibroGen, Inc.'s current dividend yield is 0.30%.
What are FibroGen, Inc.'s profit margins?
FibroGen, Inc. has 47.5% gross margin and -507.8% operating margin.